



ATTORNEYS AT LAW



Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Donald J. Featherstone  
Timothy J. Shea, Jr  
Michael V. Messinger

Judith U. Kim  
Patrick E. Garrett  
Jeffrey T. Helvey  
Heidi L. Kraus  
Eldora L. Ellison  
Thomas C. Fiala  
Donald R. Banowitz  
Peter A. Jackman  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Brian J. Del Buono  
Virgil Lee Beason  
Theodore A. Wood  
Elizabeth J. Haanes  
Joseph S. Ostroff  
Frank R. Cottingham  
Rae Lynn P. Guest

Daniel A. Klein  
Jason D. Eisenberg  
Michael D. Specht  
Tracy L. Muller  
Jon E. Wright  
LuAnne M. DeSantis  
Ann E. Summerfield  
Helene C. Carlson  
Cynthia M. Bouchez  
Timothy A. Doyle  
Gaby L. Longworth  
Lori A. Gordon  
Nicole D. Dretar  
Ted J. Ebersole  
Laura A. Vogel  
Bryan S. Wade  
Aaron L. Schwartz  
Shannon A. Carroll\*

Wesley W. Jones\*  
Matthew E. Kelley\*  
Michelle K. Holoubek\*  
Marsha A. Rose\*

**Registered Patent Agents\***  
Karen R. Markowicz  
Nancy J. Leith  
Matthew J. Dowd  
Katrina Yujian Pei Quach  
Bryan L. Skelton  
Robert A. Schwartzman  
Teresa A. Colella  
Victoria S. Rutherford  
Simon J. Elliott  
Julie A. Heider  
Mita Mukherjee  
Scott M. Woodhouse

Christopher J. Walsh  
Liliana Di Nola-Baron  
Peter A. Socarras  
Jeffrey Mills  
Danielle L. Letting

**Of Counsel**  
Kenneth C. Bass III  
Marvin C. Guthrie

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Practice Limited to  
Federal Agencies

January 24, 2006

**WRITER'S DIRECT NUMBER:**  
(202) 772-8834

**INTERNET ADDRESS:**  
BHAANES@SKGF.COM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Art Unit 1649**  
**Mail Stop Amendment**

Re: U.S. Utility Patent Application  
Application No. 10/735,256; Filed: December 12, 2003  
For: **Nogo Receptor Homologs**  
Inventors: **STRITTMATTER et al.**  
Our Ref: 2159.0420002/EJH/SAC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Credit Card Payment Form (PTO-2038) in the amount of \$180.00 to cover: \$180.00 - Fee for Submission of an Information Disclosure Statement;
2. Second Supplemental Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(c);
- 3.. A listing of the cited documents on Form PTO/SB/O8B (1 sheet);
4. A copy of the cited documents AR2, AS2, AT2, AR3, AS3, AT3 and AR4; and
5. One (1) return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
January 24, 2006  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Elizabeth J. Haanes, Ph.D.  
Attorney for Applicants  
Registration No. 42,613

Reg. # 94,161

EJH/SAC/jk  
Enclosures



UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

STRITTMATTER *et al.*

Appl. No.: 10/735,256

Filed: December 12, 2003

For: **Nogo Receptor Homologs**

Confirmation No.: 9794

Art Unit: 1649

Examiner: WANG, Chang YU

Atty. Docket: 2159.0420002/EJH/SAC

**Second Supplemental Information Disclosure Statement  
Filing Under 37 C.F.R. § 1.97(c)**

*Mail Stop Amendment*

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on June 23, 2005 in connection with the above-captioned application. Copies of the documents are submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Form PTO/SB/08B based on information presently available to the undersigned. However, the listed

publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO/SB/08B, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Elizabeth J. Haanes, Ph.D. *for Reg # 24,161*  
Attorney for Applicants  
Registration No. 42,613

Date: 1/24/06

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

485757\_1.DOC



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/735,256
				Filing Date	December 12, 2003
				First Named Inventor	Stephen M. STRITTMATTER
				Art Unit	1649
				Examiner Name	Wang, Chang Yu
Sheet	1	of	1	Attorney Docket Number	2159.0420002/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AR2	Domeniconi, M., <i>et al.</i> , "Myelin-Associated Glycoprotein Interacts with the Nogo66 Receptor to Inhibit Neurite Outgrowth," <i>Neuron</i> 35:283-290, Cell Press (July 2002)	
	AS2	GrandPré, T., <i>et al.</i> , "Nogo-66 receptor antagonist peptide promotes axonal regeneration," <i>Nature</i> 417:547-551, Nature Publishing Group (May 2002)	
	AT2	International Search Report for International Application No. PCT/US2005/002535, European Patent Office, Netherlands, mailed October 24, 2005	
	AR3	Li, M., <i>et al.</i> , "Effect of soluble Nogo receptor treatment on functional and histological outcome after spinal cord injury in the rat," Biosis Database, Accession No. PREV200400194121, Abstract No. 80.22, <i>Presented at the 33rd Annual Meeting of the Society of Neuroscience</i> , New Orleans, LA (November 8-12, 2003)	
	AS3	Li, W., <i>et al.</i> , "A Neutralizing Anti-Nogo66 Receptor Monoclonal Antibody Reverses Inhibition of Neurite Outgrowth by Central Nervous System Myelin," <i>J. Biol. Chem.</i> 42:43780-43788, The American Society for Biochemistry and Molecular Biology, Inc. (October 2004)	
	AT3	Li, W., <i>et al.</i> , "Neutralization of NGR1 May Be Sufficient to Promote Rat DRG Neurite Outgrowth in the Presence of CNS Myeline," SFN 2003 Abstract Viewer & Itinerary Planner, Program No. 678.3, <i>Presented at the 33rd Annual Meeting of the Society of Neuroscience</i> , New Orleans, LA (November 8-12, 2003)	
	AR4	Oertle, T., <i>et al.</i> , "Nogo-A Inhibits Neurite Outgrowth and Cell Spreading with Three Discrete Regions," <i>J. Neurosci.</i> 23:5393-5406, Society for Neuroscience (July 2003)	

485763\_1.DOC

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.